1 Venter JC, "The sequence of the human genome" 291 : 1304-1351, 2001
2 Tönjes A, "The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk" 10 : 410-414, 2007
3 Stumvoll M, "The peroxisome proliferator–activated receptor-γ2 Pro12Ala polymorphism" 51 : 2341-2347, 2002
4 Caramori ML, "The human Peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes" 52 : 3010-3013, 2003
5 Mori H, "The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes" 50 : 891-894, 2001
6 Jorsal A, "The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy" 94 : 347-351, 2008
7 Desvergne B, "Peroxisome proliferator-activated receptors: nuclear control of metabolism" 20 : 649-688, 1999
8 Herrmann SM, "Peroxisome proliferator-activated receptor-γ 2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes" 51 : 2653-2657, 2002
9 Pollex RL, "Peroxisome proliferator-activated receptor g polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes" 21 : 166-171, 2007
10 이규호, "Peroxisome Proliferators-Activated Receptor γ2 Pro12Ala 유전자 다형성과 당뇨병성 신증과의 연관성조사" 대한당뇨병학회 32 (32): 402-408, 2008
1 Venter JC, "The sequence of the human genome" 291 : 1304-1351, 2001
2 Tönjes A, "The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk" 10 : 410-414, 2007
3 Stumvoll M, "The peroxisome proliferator–activated receptor-γ2 Pro12Ala polymorphism" 51 : 2341-2347, 2002
4 Caramori ML, "The human Peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes" 52 : 3010-3013, 2003
5 Mori H, "The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes" 50 : 891-894, 2001
6 Jorsal A, "The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy" 94 : 347-351, 2008
7 Desvergne B, "Peroxisome proliferator-activated receptors: nuclear control of metabolism" 20 : 649-688, 1999
8 Herrmann SM, "Peroxisome proliferator-activated receptor-γ 2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes" 51 : 2653-2657, 2002
9 Pollex RL, "Peroxisome proliferator-activated receptor g polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes" 21 : 166-171, 2007
10 이규호, "Peroxisome Proliferators-Activated Receptor γ2 Pro12Ala 유전자 다형성과 당뇨병성 신증과의 연관성조사" 대한당뇨병학회 32 (32): 402-408, 2008
11 Auwerx J, "PPARgamma, the ultimate thrifty gene" 42 : 1033-1049, 1999
12 Spiegelman BM, "PPAR-gamma: adipogenic regulator and thiazolidinedione receptor" 47 : 507-514, 1998
13 Lander ES, "Initial sequencing and analysis of the human genome" 409 : 860-921, 2001
14 Masugi J, "Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferatoractivated receptor-gamma 2 on thiazolidinedione-induced adipogenesis" 268 : 178-182, 2000
15 Vigouroux C, "Human peroxisome proliferatoractivated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes" 47 : 490-492, 1998
16 Beamer BA, "Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene" 233 : 756-759, 1997
17 Ridker PM, "Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction" 23 : 859-863, 2003
18 Deeb SS, "A Pro12Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity" 20 : 284-287, 1998